Multi-Indication Pricing: Big Hurdles And Actionable Options
Executive Summary
Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.
You may also be interested in...
Express Scripts Adds Gilead’s Harvoni To 2017 Formularies
The pharmacy benefit manager says it has been able to negotiate a discount with Gilead enabling it to give both Harvoni and AbbVie’s Viekira Pak preferred formulary placement. Express Scripts also is expanding its indication-based oncology management initiative.
Oncology Booming But Cost Outlook Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new report.
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
As agency issues take center stage at a pharmacoeconomics meeting, American Enterprise Institute fellow recommends reorganizing review divisions to accelerate approval of orphan drugs.